Page 3«..2345..1020..»

ECMOHO to Announce Third Quarter 2020 Unaudited Financial Results

By Dr. Matthew Watson

SHANGHAI, China, Nov. 27, 2020 (GLOBE NEWSWIRE) -- ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the “Company”), a leading integrated solutions provider in the non-medical health and wellness market in China, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2020 on Monday, November 30, 2020.

Read the original:
ECMOHO to Announce Third Quarter 2020 Unaudited Financial Results

To Read More: ECMOHO to Announce Third Quarter 2020 Unaudited Financial Results
categoriaGlobal News Feed commentoComments Off on ECMOHO to Announce Third Quarter 2020 Unaudited Financial Results | dataNovember 28th, 2020
Read All

Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

By Dr. Matthew Watson

Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with anemia of CKD not on dialysis Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with anemia of CKD not on dialysis

The rest is here:
Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

To Read More: Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
categoriaGlobal News Feed commentoComments Off on Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis | dataNovember 28th, 2020
Read All

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement…

By Dr. Matthew Watson

CAMBRIDGE, Mass., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.

Go here to read the rest:
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement...

To Read More: Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement…
categoriaGlobal News Feed commentoComments Off on Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement… | dataNovember 28th, 2020
Read All

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with…

By Dr. Matthew Watson

Here is the original post:
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with...

To Read More: Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with…
categoriaGlobal News Feed commentoComments Off on Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with… | dataNovember 28th, 2020
Read All

Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences

By Dr. Matthew Watson

FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate at two upcoming virtual investor conferences in December, including:

View original post here:
Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences

To Read More: Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences
categoriaGlobal News Feed commentoComments Off on Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences | dataNovember 28th, 2020
Read All

DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded…

By Dr. Matthew Watson

SAN DIEGO, Nov. 27, 2020 (GLOBE NEWSWIRE) -- SmartPharm Therapeutics, Inc. (“SmartPharm”), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and developer of next-generation, non-viral gene therapy technologies, announced today that it has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) co-funded by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to develop a rapid countermeasure to COVID-19. The contract would provide SmartPharm up to USD $34 million for development through Phase 2 clinical studies of a gene-encoded antibody (“Gene MAb”) that could enable rapid protection from and/or treatment of SARS-CoV-2 infection and COVID-19. Sorrento will seek further funding in support of the COVID Gene MAb program toward EUA (emergency use authorization) approval and large-scale manufacturing pending successful clinical studies.

Read the original here:
DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded...

To Read More: DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded…
categoriaGlobal News Feed commentoComments Off on DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded… | dataNovember 28th, 2020
Read All

CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy’s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell & Gene…

By Dr. Matthew Watson

MALVERN, Pa., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on “The Promise of Cell & Gene Therapies: Regulatory and Reimbursement Roadblocks” at Xconomy’s Xcelerating Life Sciences New York & Philadelphia Virtual Event on December 3 at 10:30 a.m. This panel will be moderated by Theresa Lavoie, Principal, Fish & Richardson and also feature panelists, Greg White, Senior Director, Global Market Access Policy – Janssen, Pharmaceutical Companies and Snehal Naik, Global Regulatory Affair- Advanced Therapies, Janssen R&D.

More here:
CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy’s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell & Gene...

To Read More: CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy’s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell & Gene…
categoriaGlobal News Feed commentoComments Off on CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy’s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell & Gene… | dataNovember 28th, 2020
Read All

Spectral Medical to Host Virtual Investor Day on December 4, 2020

By Dr. Matthew Watson

TORONTO, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly owned subsidiary Dialco Medical Inc. (“Dialco”), today announced the details for the Company’s upcoming Virtual Investor Day, scheduled to be held on Friday, December 4, 2020 at 10:00 a.m. EST.

Read this article:
Spectral Medical to Host Virtual Investor Day on December 4, 2020

To Read More: Spectral Medical to Host Virtual Investor Day on December 4, 2020
categoriaGlobal News Feed commentoComments Off on Spectral Medical to Host Virtual Investor Day on December 4, 2020 | dataNovember 28th, 2020
Read All

Tauriga Sciences Inc. Sets New Daily E-Commerce Records for Both: Revenue Generated [$9,514.49] and Individual Online Orders [103 Total]

By Dr. Matthew Watson

Read more here:
Tauriga Sciences Inc. Sets New Daily E-Commerce Records for Both: Revenue Generated [$9,514.49] and Individual Online Orders [103 Total]

To Read More: Tauriga Sciences Inc. Sets New Daily E-Commerce Records for Both: Revenue Generated [$9,514.49] and Individual Online Orders [103 Total]
categoriaGlobal News Feed commentoComments Off on Tauriga Sciences Inc. Sets New Daily E-Commerce Records for Both: Revenue Generated [$9,514.49] and Individual Online Orders [103 Total] | dataNovember 28th, 2020
Read All

Ceapro Inc. Reports 2020 Third Quarter and Nine-Month Financial Results and Operational Highlights

By Dr. Matthew Watson

– R&D activities focused on advancing the development of innovative delivery systems and yeast beta glucan as a potential inhalable therapeutic for COVID-19 –

See the original post:
Ceapro Inc. Reports 2020 Third Quarter and Nine-Month Financial Results and Operational Highlights

To Read More: Ceapro Inc. Reports 2020 Third Quarter and Nine-Month Financial Results and Operational Highlights
categoriaGlobal News Feed commentoComments Off on Ceapro Inc. Reports 2020 Third Quarter and Nine-Month Financial Results and Operational Highlights | dataNovember 28th, 2020
Read All

USAN Modifies Lead Drug Candidate’s Chemical Name to ‘Simufilam’

By Dr. Matthew Watson

Future References to Lead Drug Candidate for Alzheimer’s Disease Will Be Simufilam Future References to Lead Drug Candidate for Alzheimer’s Disease Will Be Simufilam

Original post:
USAN Modifies Lead Drug Candidate’s Chemical Name to ‘Simufilam’

To Read More: USAN Modifies Lead Drug Candidate’s Chemical Name to ‘Simufilam’
categoriaGlobal News Feed commentoComments Off on USAN Modifies Lead Drug Candidate’s Chemical Name to ‘Simufilam’ | dataNovember 28th, 2020
Read All

Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting

By Dr. Matthew Watson

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the presentation of clinical data at the upcoming American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5-8, 2020.

Read more:
Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting

To Read More: Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting
categoriaGlobal News Feed commentoComments Off on Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting | dataNovember 26th, 2020
Read All

C4 Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx

By Dr. Matthew Watson

WATERTOWN, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will present at the Evercore ISI 3rd Annual HealthCONx on Thursday, December 3, 2020 at 8:25 a.m. ET.

Visit link:
C4 Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx

To Read More: C4 Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx
categoriaGlobal News Feed commentoComments Off on C4 Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx | dataNovember 26th, 2020
Read All

Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence…

By Dr. Matthew Watson

Simple, single-dose nasal spray offers greater ease and comfort of administration; positioning AdCOVID as a differentiated vaccine candidate for adults and children

Excerpt from:
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence...

To Read More: Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence…
categoriaGlobal News Feed commentoComments Off on Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence… | dataNovember 26th, 2020
Read All

Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference

By Dr. Matthew Watson

LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, will participate in a fireside chat hosted by Umer Raffat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 from 10:55 AM – 11:15 AM EST.

Follow this link:
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference

To Read More: Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference
categoriaGlobal News Feed commentoComments Off on Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference | dataNovember 26th, 2020
Read All

Cronos Group Inc. to Speak at the Cowen 2020 Boston Cannabis Conference

By Dr. Matthew Watson

TORONTO, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, is scheduled to speak on a panel at the Cowen 2020 Boston Cannabis Conference on Wednesday, December 2, 2020 at 9:20 a.m. EST.

Continue reading here:
Cronos Group Inc. to Speak at the Cowen 2020 Boston Cannabis Conference

To Read More: Cronos Group Inc. to Speak at the Cowen 2020 Boston Cannabis Conference
categoriaGlobal News Feed commentoComments Off on Cronos Group Inc. to Speak at the Cowen 2020 Boston Cannabis Conference | dataNovember 26th, 2020
Read All

Novavax to Participate in Upcoming Conferences

By Dr. Matthew Watson

GAITHERSBURG, Md., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion in each conference.

Go here to see the original:
Novavax to Participate in Upcoming Conferences

To Read More: Novavax to Participate in Upcoming Conferences
categoriaGlobal News Feed commentoComments Off on Novavax to Participate in Upcoming Conferences | dataNovember 26th, 2020
Read All

Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference

By Dr. Matthew Watson

AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the Evercore ISI 3rd Annual HealthCONx conference being held December 1-3, 2020.

More:
Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference

To Read More: Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference
categoriaGlobal News Feed commentoComments Off on Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference | dataNovember 26th, 2020
Read All

FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma

By Dr. Matthew Watson

NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug Administration (“FDA”) has approved DANYELZA (naxitamab-gqgk) 40mg/10ml. DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication is approved under accelerated approval regulation based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial. DANYELZA is a humanized, monoclonal antibody that targets the ganglioside GD2, which is highly expressed in various neuroectoderm-derived tumors and sarcomas. DANYELZA is administered to patients three times in a week in an outpatient setting and the treatment is repeated every four weeks. The product has received Priority Review, Orphan Drug, Breakthrough Therapy, and Rare Pediatric Disease designations from the FDA.

See more here:
FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma

To Read More: FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma
categoriaGlobal News Feed commentoComments Off on FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma | dataNovember 26th, 2020
Read All

Half-year report

By Dr. Matthew Watson

DXS INTERNATIONAL PLC

View post:
Half-year report

To Read More: Half-year report
categoriaGlobal News Feed commentoComments Off on Half-year report | dataNovember 26th, 2020
Read All

Page 3«..2345..1020..»